SRSF3 Antibody

What is SRSF3 and what are its primary biological functions?

SRSF3, also known as SRP20 or SFRS3, is a splicing factor that plays multiple crucial roles in RNA processing. Its primary functions include acting as a splicing regulator by binding the consensus motif 5'-C[ACU][AU]C[ACU][AC]C-3' within pre-mRNA to promote specific exon inclusion during alternative splicing . SRSF3 also facilitates mRNA nuclear export by functioning as an adapter protein that binds mRNA which is then transferred to the NXF1-NXT1 heterodimer for export via the TAP/NXF1 pathway . Additionally, SRSF3 enhances NXF1-NXT1 RNA-binding activity and participates in m6A-mediated RNA processing through its interaction with YTHDC1, a RNA-binding protein that recognizes N6-methyladenosine-containing RNAs . This interaction promotes recruitment of SRSF3 to its mRNA-binding elements adjacent to m6A sites within exons and facilitates nuclear export of these modified transcripts .

What types of SRSF3 antibodies are commercially available for research?

Several types of SRSF3 antibodies are available for research applications. These include rabbit polyclonal antibodies such as ab73891 and ab125124, which are generated using synthetic peptides within human SRSF3 as immunogens . These antibodies have been validated for various applications including Western Blotting (WB), Immunocytochemistry/Immunofluorescence (ICC/IF), and Immunohistochemistry-Paraffin (IHC-P) . Additionally, antibodies like ProteinTech Group Cat no. 10916-1-AP have been successfully used in immunohistochemistry studies of SRSF3 expression in cancer tissues . While these antibodies are primarily validated for human samples, they may cross-react with other species based on sequence homology, though such applications would require additional validation.

How should I select the appropriate SRSF3 antibody for my specific experimental application?

When selecting an SRSF3 antibody for your research, several factors should be considered to ensure optimal results. First, verify the antibody's validation for your specific application (Western blotting, immunohistochemistry, or immunofluorescence) by reviewing the manufacturer's documentation . Second, confirm the antibody's species reactivity matches your experimental model, as most commercially available antibodies are validated primarily for human samples .

For studies involving phosphorylated SRSF3, consider whether you need an antibody that specifically recognizes phosphorylated epitopes, or whether a combination approach (such as immunoprecipitation with anti-Akt phosphosubstrate antibody followed by Western blotting with anti-SRSF3 antibody) would be more appropriate . Review the validation data provided by the manufacturer, including Western blot images and immunofluorescence patterns, and check if the antibody has been cited in peer-reviewed publications, particularly in applications similar to your intended use . For cancer biomarker studies, select antibodies that have demonstrated consistent results in tissue microarray analyses across multiple cancer types .

What are the optimal protocols for Western blot detection of SRSF3?

For optimal Western blot detection of SRSF3, several technical considerations should be addressed. Since SRSF3 is approximately 20-25 kDa, use 12-15% SDS-PAGE gels for optimal resolution in the lower molecular weight range . For sample preparation, careful separation of nuclear and cytoplasmic fractions is important when studying SRSF3's subcellular distribution, as it functions in both compartments .

When using antibody ab73891, a recommended dilution is 1/500 for Western blotting, though performing a dilution series (1/250, 1/500, 1/1000) can help determine the optimal concentration for your specific sample type . Include appropriate controls, such as positive controls (cell lines known to express SRSF3) and negative controls (SRSF3 knockdown/knockout samples when available) . For phosphorylation studies, researchers have successfully used a combination approach: immunoprecipitation with anti-Akt phosphosubstrate antibody followed by Western blotting with anti-SRSF3 antibody . This method revealed that phosphorylated SRSF3 shows different temporal patterns in cytoplasmic versus nuclear fractions following growth factor stimulation, with peak levels occurring at different timepoints .

How can I optimize immunohistochemical detection of SRSF3 in tissue samples?

For effective immunohistochemical detection of SRSF3 in tissue samples, begin by deparaffinizing slides in xylene and rehydrating with graded alcohol . Implement an appropriate antigen retrieval method suitable for formalin-fixed paraffin-embedded tissues to expose epitopes that may have been masked during fixation . Block non-specific binding by incubating slides with 10% goat serum in phosphate buffered saline for 10 minutes at room temperature .

For primary antibody incubation, use SRSF3 polyclonal antibody at an optimized dilution (1:100 dilution has been successful in pan-cancer studies) and incubate at 4°C overnight for optimal binding . Follow with an appropriate secondary antibody such as Goat Anti-Rabbit IgG (H+L), ensuring compatibility with your detection system . Counterstain with hematoxylin to visualize tissue architecture, which provides context for SRSF3 expression patterns .

For quantitative analysis, evaluate staining intensity using image analysis software (such as Image Pro Plus 6.0) to measure integrated optical density (IOD) in the area of positive cells or IOD per area of positive cells (mean intensity) . This methodology has been successfully applied to compare SRSF3 expression between normal and tumor tissues across multiple cancer types, demonstrating significant differences in expression patterns that correlate with clinical outcomes .

How can I investigate the subcellular localization of SRSF3 using antibody-based approaches?

Investigating SRSF3's subcellular localization is critical for understanding its diverse functions in RNA processing. For immunofluorescence studies, fix cells with an appropriate fixative (typically 4% paraformaldehyde) and permeabilize with a suitable detergent . Use anti-SRSF3 antibodies such as ab73891 or ab125124 at optimized dilutions, followed by fluorophore-conjugated secondary antibodies . Counterstain nuclei with DAPI or Hoechst and image using confocal microscopy for optimal resolution of nuclear speckles and cytoplasmic distribution.

For biochemical fractionation approaches, separate nuclear and cytoplasmic fractions using established protocols and confirm fractionation quality using compartment-specific markers (e.g., Lamin B for nuclear fraction, GAPDH for cytoplasmic fraction) . Perform Western blotting on each fraction to quantify relative amounts of SRSF3 in different cellular compartments .

To study dynamic changes in SRSF3 localization, particularly in response to signaling events, implement time-course experiments. Research examining PI3K-mediated PDGFRα signaling demonstrated that phosphorylated SRSF3 showed distinctive temporal patterns in different cellular compartments following PDGF-AA stimulation . Specifically, phosphorylated SRSF3 peaked in the cytoplasmic fraction at 15 minutes (3.741±1.527-fold induction over unstimulated levels) and in the nuclear fraction at 60 minutes (2.455±0.7326-fold induction) . These differential kinetics provide insight into how post-translational modifications regulate SRSF3's trafficking between cellular compartments.

How is SRSF3 expression related to cancer prognosis and what methodologies are used to study this correlation?

The methodological approach to establish these correlations typically involves immunohistochemical staining of tissue microarrays containing matched tumor and normal tissues, with quantification of staining intensity using digital pathology software . This is followed by statistical analysis correlating expression levels with clinical parameters such as survival metrics, tumor stage, and metastatic status . In a comprehensive study across multiple cancer types, SRSF3 expression was consistently upregulated in cancerous tissues compared to normal tissues, with significant differences confirmed in twelve cancer types including cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, glioblastoma multiforme, and others .

These findings collectively suggest that SRSF3 overexpression is associated with cancer progression and poorer outcomes, positioning it as a potential prognostic biomarker with clinical utility across multiple cancer types .

What is the relationship between SRSF3 and immune cell infiltration in the tumor microenvironment?

The relationship between SRSF3 expression and the tumor immune microenvironment is complex and varies across cancer types . SRSF3 expression shows positive correlation with immune cell infiltration in certain cancer types, as determined through comprehensive analysis of infiltration scores for various immune cells including B cells, T cell subsets, natural killer cells, macrophages, and dendritic cells .

SRSF3 exhibits significant co-expression with CD276 (B7-H3), a potential immune checkpoint molecule considered a promising tumor immunotherapy target . This suggests SRSF3 may play an important role in tumor immunity regulation. In kidney chromophobe (KICH) and liver hepatocellular carcinoma (LIHC), SRSF3 is significantly co-expressed with multiple immune checkpoint genes, suggesting it may regulate tumor immune response through checkpoint activity in these cancers .

Interestingly, SRSF3 shows different patterns of correlation with immune checkpoints across cancer types. It is negatively correlated with most immune checkpoints in breast invasive carcinoma (BRCA), glioblastoma multiforme (GBM), brain lower grade glioma (LGG), and testicular germ cell tumors (TGCT), suggesting a potentially negative regulatory role in tumor immunity in these contexts . These differential correlations highlight the context-dependent role of SRSF3 in modulating the tumor immune microenvironment and suggest potential implications for immunotherapy response in different cancer types.

What methods can be used to investigate SRSF3's functional role in cancer progression?

Investigating SRSF3's functional role in cancer progression requires a multi-faceted approach combining molecular, cellular, and in vivo methodologies. Loss and gain-of-function experiments using lentivirus-mediated knockdown and overexpression systems in cancer cell lines provide direct evidence of SRSF3's impact on cancer cell behavior . These approaches can be used to assess effects on proliferation, apoptosis, migration, invasion, and therapy response .

Western blot analysis detecting the expression level of apoptosis-related proteins in cancer cell lines following SRSF3 manipulation can reveal mechanisms by which SRSF3 influences cell survival pathways . Additionally, correlation analyses between SRSF3 expression and genomic features such as tumor mutation burden (TMB) and microsatellite instability (MSI) provide insight into potential interactions between SRSF3 and genomic instability in cancer .

SRSF3 expression shows positive correlation with high mutation status in multiple cancers including adrenocortical carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, colon adenocarcinoma, and others . Significant correlation between SRSF3 expression and microsatellite instability was observed in 11 out of 33 cancer types analyzed . These findings suggest SRSF3 may influence genomic stability or be co-regulated with pathways involved in maintaining genomic integrity, providing additional mechanisms by which SRSF3 could impact cancer progression beyond its direct RNA processing functions.

How does SRSF3 contribute to pluripotency and stem cell maintenance?

SRSF3 plays a critical role in maintaining pluripotency and facilitating cellular reprogramming through several key mechanisms. Research has demonstrated that SRSF3 promotes pluripotency through the export and processing of Nanog mRNA, a core transcription factor essential for stem cell self-renewal and pluripotency . When SRSF3 is knocked out in induced pluripotent stem cells (iPSCs), there is a notable decrease in pluripotency marker expression, including Nanog, within 24 hours of knockout induction .

Experimental evidence shows that SRSF3 overexpression significantly enhances reprogramming efficiency. When mouse embryonic fibroblasts (MEFs) were transduced with Srsf3 and a GFP reporter before doxycycline-induced reprogramming, they generated significantly more alkaline phosphatase (AP)-positive colonies compared to GFP-only controls . Flow cytometric analysis of cell surface marker expression further confirmed this enhanced reprogramming efficiency .

SRSF3-depleted iPSCs show morphological changes within 24-48 hours after knockout induction, indicating rapid loss of pluripotent characteristics . Western blot analysis confirmed decreased NANOG expression in SRSF3-deficient iPSCs, and quantification of mRNA expression showed that Srsf3 knockout results in significant downregulation of pluripotency markers within 24 hours . These findings collectively demonstrate that SRSF3 is a critical regulator of pluripotency, functioning both in the establishment phase during reprogramming and in the maintenance of the pluripotent state in established stem cells.

What is the relationship between SRSF3 phosphorylation and its cellular functions?

SRSF3 undergoes phosphorylation that significantly impacts its subcellular localization and function, particularly in response to growth factor signaling . Research has shown that SRSF3 is phosphorylated at Akt consensus sites downstream of PI3K-mediated PDGFRα signaling in mouse palatal mesenchyme cells . This phosphorylation occurs in response to PDGF-AA ligand stimulation and shows distinct temporal patterns in different cellular compartments .

The methodological approach to study this phosphorylation involves immunoprecipitation of phosphorylated Akt substrates from fractionated lysates using anti-Akt phosphosubstrate antibody, followed by western blotting with anti-SRSF3 antibody . This approach allowed researchers to track phosphorylated SRSF3's distribution between cytoplasmic and nuclear compartments over time .

In response to PDGF-AA stimulation, phosphorylated SRSF3 peaked in the cytoplasmic fraction at 15 minutes post-stimulation (3.741±1.527-fold induction over unstimulated levels) and in the nuclear fraction at 60 minutes post-stimulation (2.455±0.7326-fold induction) . These distinct temporal patterns suggest phosphorylation may regulate SRSF3's shuttling between nucleus and cytoplasm, potentially impacting its various functions including alternative splicing regulation, mRNA export, and interactions with other RNA-binding proteins . This phosphorylation-dependent regulation provides a mechanism by which cells can rapidly modulate RNA processing and export in response to external stimuli.

How does SRSF3 interact with N6-methyladenosine (m6A)-modified RNAs?

SRSF3's interaction with N6-methyladenosine (m6A)-modified RNAs represents an important intersection between epitranscriptomic regulation and RNA processing . SRSF3 interacts with YTHDC1, a specialized RNA-binding protein that specifically recognizes and binds to m6A-containing RNAs . This interaction is crucial for the recruitment of SRSF3 to its mRNA-binding elements that are adjacent to m6A sites within exons .

The SRSF3-YTHDC1 interaction promotes recruitment of SRSF3 to m6A-modified sites within exons, where SRSF3 binds its consensus motif 5'-C[ACU][AU]C[ACU][AC]C-3' within pre-mRNA . This binding promotes specific exon inclusion during alternative splicing, thereby linking m6A modification to splicing regulation .

Beyond splicing regulation, SRSF3 plays a critical role in the nuclear export of m6A-containing mRNAs . The interaction between SRSF3 and YTHDC1 facilitates m6A-containing mRNA binding to both SRSF3 and NXF1 (Nuclear RNA Export Factor 1), a key component of the mRNA nuclear export machinery . SRSF3 enhances NXF1-NXT1 RNA-binding activity, promoting efficient nuclear export of m6A-modified mRNAs .

This creates a mechanistic model where m6A modification of RNA leads to recognition by YTHDC1, recruitment of SRSF3 to adjacent binding sites, enhanced interaction with nuclear export machinery, and ultimately efficient export of m6A-modified mRNAs . These findings highlight SRSF3's role as a critical mediator between RNA modifications and RNA fate determination.

What are common challenges when using SRSF3 antibodies and how can they be addressed?

When working with SRSF3 antibodies, researchers may encounter several technical challenges that can be systematically addressed through optimization strategies. For Western blotting applications, high background across the membrane can be mitigated by increasing blocking time or concentration (e.g., 5% BSA or milk for 1-2 hours), optimizing antibody dilution, and increasing washing duration and frequency . Multiple bands may appear due to post-translational modifications of SRSF3 or non-specific binding; researchers should verify if bands represent modified forms of SRSF3 (phosphorylated, SUMOylated, etc.) and use positive controls (e.g., recombinant SRSF3) and negative controls (e.g., SRSF3 knockout samples) .

For immunohistochemistry and immunofluorescence, high background can be addressed by optimizing blocking conditions (10% goat serum was effective in referenced studies) and titrating primary antibody concentration (1:100 dilution was successful in the pan-cancer study) . Since SRSF3 is primarily nuclear with some cytoplasmic localization, distinguishing specific nuclear staining from non-specific binding requires comparison with known expression patterns and inclusion of appropriate controls .

Validation approaches such as peptide competition (pre-incubating antibody with the immunizing peptide), siRNA/shRNA knockdown controls, and using multiple antibodies targeting distinct epitopes of SRSF3 can help confirm specificity . For studies involving phosphorylated SRSF3, phosphatase inhibitors must be included in lysis buffers, and for subcellular distribution studies, careful fractionation protocols should be followed to avoid cross-contamination .

What controls should be included in experiments using SRSF3 antibodies?

Robust experimental design with appropriate controls is essential when using SRSF3 antibodies. For all applications, essential controls include positive samples known to express SRSF3 (e.g., HeLa cells for human studies), negative controls (both technical negative: primary antibody omission, and biological negative: SRSF3 knockdown/knockout samples when available), and loading/processing controls to ensure equal sample processing across experimental conditions .

For Western blotting, include molecular weight markers to confirm the expected size of SRSF3 (~20-25 kDa) and housekeeping proteins for normalization . When conducting subcellular fractionation studies, include nuclear markers (e.g., Lamin B, Histone H3) and cytoplasmic markers (e.g., GAPDH, α-tubulin) to verify fractionation quality . For phosphorylation studies, consider controls such as lambda phosphatase treatment of samples and positive controls from cells treated with phosphatase inhibitors .

In immunohistochemistry and immunofluorescence, include tissues or cell types with known expression patterns, antibody concentration gradients to determine optimal concentration, and secondary antibody-only controls to assess background . Nuclear counterstains like DAPI or hematoxylin provide context for localization patterns .

For functional studies of SRSF3, include gain-of-function (SRSF3 overexpression) and loss-of-function (SRSF3 knockdown or knockout) models . In the PI3K-mediated PDGFRα signaling study, researchers effectively used unstimulated cells as controls and measured fold induction of phosphorylated SRSF3 relative to these baseline levels, allowing for quantitative assessment of signaling-induced changes .

How can SRSF3 antibody data be integrated with other experimental approaches?

To gain a comprehensive understanding of SRSF3's functions and mechanisms, integrating antibody-based detection with complementary experimental approaches is essential . Researchers can combine protein-level data from antibody-based methods with transcriptomics (RNA-seq to identify global splicing changes upon SRSF3 manipulation), epitranscriptomics (m6A-seq to correlate m6A modification with SRSF3 binding), and genomics (ChIP-seq of factors that may cooperate with SRSF3) .

For RNA-binding assessment, antibody-based protein detection can be complemented with techniques such as CLIP-seq (Cross-linking immunoprecipitation) to identify direct RNA targets of SRSF3, RNA immunoprecipitation (RIP) to identify RNA-protein complexes, and in vitro binding assays to characterize binding motifs and affinities . This integration allows researchers to map SRSF3 binding sites relative to alternatively spliced exons and correlate binding with m6A modification sites .

Functional studies can combine antibody-based expression/localization data with splicing reporter assays, minigene assays to evaluate SRSF3's impact on exon inclusion/exclusion, and nuclear export assays to quantify SRSF3's role in mRNA export . For signaling pathway integration, phospho-specific detection can be complemented with kinase inhibitor studies, phosphatase treatments, and phospho-mimetic or phospho-dead mutants to assess functional consequences .

In clinical applications, tissue-based antibody detection can be integrated with patient outcome data, genomic alterations affecting SRSF3 or its pathway, and treatment response information . This multi-modal approach has successfully revealed SRSF3's role in cancer progression, pluripotency maintenance, and RNA modification pathways .